Zai Lab (BMV:ZLAB N) - Hisse Senedi Fiyatı, Haberler ve Analizler

ZLAB N Stoklara Genel Bakış

Zai Lab Limited onkoloji, otoimmün bozukluklar, bulaşıcı hastalıklar ve nörobilim tedavilerine yönelik terapiler geliştirmekte ve ticarileştirmektedir. Daha fazla detay

ZLAB N temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 80.4% daha düşük bir oranda işlem görüyor

Kazançların yılda 68.17% oranında artması öngörülüyor

Risk Analizi

Hisse senetleri oldukça likit değildir

Zai Lab Limited Rakipler

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.9b

Suzhou Zelgen BiopharmaceuticalsLtd

SHSE:688266

CN¥17.5b

Twist Bioscience

NasdaqGS:TWST

US$2.5b

ACADIA Pharmaceuticals

NasdaqGS:ACAD

US$2.7b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Zai Lab
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$611.50
52 Haftanın En Yüksek Seviyesi	US$611.50
52 Haftanın En Düşük Seviyesi	US$270.64
Beta	1.04
11 Aylık Değişim	8.09%
3 Aylık Değişim	n/a
1 Yıllık Değişim	n/a
33 Yıllık Değişim	-65.77%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-58.68%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	ZLAB N	MX Biotechs	MX Pazar
7D	0%	0%	0%
1Y	n/a	0%	0%

Getiri vs. Endüstri: ZLAB N un MX Biotechs sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Getiri vs Piyasa: ZLAB N un MX Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Fiyat Oynaklığı

Is ZLAB N's price volatile compared to industry and market?
ZLAB N volatility
ZLAB N Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

İstikrarlı Hisse Senedi Fiyatı: ZLAB N hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ZLAB N 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2013	2,175	Samantha Du	www.zailaboratory.com

Zai Lab Limited, onkoloji, otoimmün bozukluklar, bulaşıcı hastalıklar ve nörobilim tedavilerine yönelik terapiler geliştirmekte ve ticarileştirmektedir. Ticari ürünleri arasında oral yoldan uygulanan bir polimeraz 1/2 inhibitörü olan Zejula; tümör hücrelerini öldürmek için belirli frekanslara ayarlanmış elektrik alanları kullanan bir kanser tedavisi olan Optune; akut bakteriyel cilt ve cilt yapısı enfeksiyonları ve toplumdan edinilmiş bakteriyel pnömoni için NUZYRA; gastrointestinal stromal tümörleri tedavi etmek için Qinlock ve myesthenia gravis için bir insan IgG1 antikor parçası olan VYVGART bulunmaktadır. Şirket ayrıca elektrik alanlarının iletimi için taşınabilir bir cihaz olan Tümör Tedavi Alanlarını; TKI ile tedavi edilmemiş veya tedavi edilmiş kanser hastalarında ROS1 ve TRK A/B/C'yi hedefleyen bir tirozin kinaz inhibitörü (TKI) olan Repotrectinib'i geliştirmektedir; Bir antikor ilaç konjugatı olan Tisotumab vedotin; KRAS-G12C mutasyonlu NSCLC, kolorektal kanser ve pankreas kanseri tedavisinde Adagrasib ve mide ve gastroözofageal kavşak kanseri hastalarını tedavi etmek için Bemarituzumab.

Zai Lab Limited Temel Bilgiler Özeti

Zai Lab'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ZLAB N temel i̇stati̇sti̇kler
Piyasa değeri	Mex$53.28b
Kazançlar(TTM)	-Mex$5.55b
Gelir(TTM)	Mex$7.29b

7.3x

P/S Oranı

-9.6x

F/K Oranı

ZLAB N aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ZLAB N gelir tablosu (TTM)
Gelir	US$355.75m
Gelir Maliyeti	US$395.21m
Brüt Kâr	-US$39.46m
Diğer Giderler	US$231.39m
Kazançlar	-US$270.85m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.75
Brüt Marj	-11.09%
Net Kâr Marjı	-76.13%
Borç/Özkaynak Oranı	16.9%

ZLAB N uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ZLAB N Stoklara Genel Bakış

Ödüller

Risk Analizi

Zai Lab Limited Rakipler

BMV:LAB B

Mex$24.9b

SHSE:688266

CN¥17.5b

NasdaqGS:TWST

US$2.5b

NasdaqGS:ACAD

US$2.7b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Zai Lab Limited has completed a Follow-on Equity Offering in the amount of $199.999994 million.

Zai Lab Limited has filed a Follow-on Equity Offering in the amount of $200 million.

Third quarter 2024 earnings released: US$0.42 loss per share (vs US$0.71 loss in 3Q 2023)

Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Zai Lab Limited Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

Zai Lab Limited Presents Data from the Ongoing Global Phase 1A/1B Study of ZL-1310

Recent updates

Zai Lab Limited has completed a Follow-on Equity Offering in the amount of $199.999994 million.

Zai Lab Limited has filed a Follow-on Equity Offering in the amount of $200 million.

Third quarter 2024 earnings released: US$0.42 loss per share (vs US$0.71 loss in 3Q 2023)

Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Zai Lab Limited Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

Zai Lab Limited Presents Data from the Ongoing Global Phase 1A/1B Study of ZL-1310

Zai Lab Limited to Report Q3, 2024 Results on Nov 12, 2024

Zai Lab Limited to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024

Zai Lab Limited to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Zai Lab Limited to Report Q2, 2024 Results on Aug 06, 2024

Zai Lab Limited Announces Executive Changes, Effective June 30, 2024

Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA

First quarter 2024 earnings released: US$0.55 loss per share (vs US$0.51 loss in 1Q 2023)

Forecast to breakeven in 2026

Zai Lab Limited to Report Q1, 2024 Results on May 08, 2024

Zai Lab Limited, Annual General Meeting, Jun 18, 2024

Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Zai Lab Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Zai Lab Limited to Report Fiscal Year 2023 Results on Feb 27, 2024

Zai Lab Announces the New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List

Zai Lab Limited to Report Q3, 2023 Results on Nov 07, 2023

Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China

Zai Lab Limited to Report Q2, 2023 Results on Aug 07, 2023

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis

Zai Lab Limited Announces Chief Financial Officer Changes, Effective July 7, 2023

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Zai Lab Limited to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

Zai Lab Limited Announces China’s National Medical Products Administration Grants Priority Review to Repotrectinib

First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.86 loss in 1Q 2022)

Zai Lab Limited to Report Fiscal Year 2022 Results on Mar 01, 2023

Zai Lab Limited Announces New Drug Application for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s National Medical Products Administration

Zai Lab Limited Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

Zai Lab Limited Appoints Michel Vounatsos to the Board of Directors

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Zai Lab Limited Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

Independent Director recently sold Mex$5.5m worth of stock

Zai Lab Limited Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary

Independent Director recently sold Mex$5.5m worth of stock

Third quarter 2022 earnings released: US$1.68 loss per share (vs US$1.01 loss in 3Q 2021)

Zai Lab Limited Announces the Appointment of Peter Huang as Chief Scientific Officer

Zai Lab Limited to Report Q3, 2022 Results on Nov 09, 2022

Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting

Second quarter 2022 earnings released: US$1.44 loss per share (vs US$1.76 loss in 2Q 2021)

Zai Lab Limited Appoints Joshua Smiley as Chief Operating Officer

Zai Lab Limited to Report Q2, 2022 Results on Aug 09, 2022

China’s National Medical Products Administration Accepts Biologics License Application of Zai Lab Limited

Zai Lab Limited Announces Breakthrough Therapy Designations Granted for Repotrectinib in China

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

First quarter 2022 earnings released: US$0.86 loss per share (vs US$2.64 loss in 1Q 2021)

Zai Lab Limited, Annual General Meeting, Jun 22, 2022

Zai Lab Limited to Report Q1, 2022 Results on May 10, 2022

No longer forecast to breakeven